ʻO ka Top 10 Biologic Drugs ma United States

Hoʻopiliʻia kēia mau lāʻau lapaʻau i nā maʻi maʻi

ʻO nā lāʻau olaola he mau lāʻau'alomo i hanaʻia mai nā molekile paʻakiki i hanaʻia me ka hoʻohanaʻana i nā microorganisms ola, nā mea kanu, a me nā pūnaewele holoholona. Hoʻonuiʻia nāʻano ola honua me ka hoʻohanaʻana i keʻenehana DNA hou. I kekahi manawa ua kapaʻia lākou heʻano biopharmaceuticals a iʻole nā ​​lāʻau lapaʻau.

Ua hoʻololi ke olakino i ka hoʻomaluʻana i nā maʻi nui a me nā maʻi kūlohelohe a ua kiʻi i nā lāʻau laulā maʻamau āpau mai kahiʻoihana kūʻai. ʻO ka'ōlohelohe Rheumatoid, kekahi mau maʻi pīpī, a me ka maʻi diabetis kaʻoi aku o ka nui o nā hōʻailona olaola i hoʻolaʻaʻia. Ke hoʻololi nei nā meaola i nāʻano hana a nā kauka i nā kūlana maʻamau i hōʻeha i nā kānaka no nā makahiki.

Bio Bioics

ʻOiaiʻo nā lāʻau lapaʻau he mau mekini i synthesiʻia mai nā meaʻokoʻa'ē aʻe, eʻoi aku ka maʻalahi o kaʻoihana biologics ma muli o kā lākou hana hana maʻamau. Ma muli o kā lākou uku kiʻekiʻe, aia kahi koi nui no nā hōʻailona likeʻole o nā lāʻau lapaʻau,ʻo ia hoʻi nāʻumi i heluʻia ma lalo nei. ʻO kekahi mauʻoihana kālai lāʻau e lobbying no ke kuleana e hana i nāʻanoʻenehana. Eia naʻe, no ka paʻakikī o ka hanaʻana, aia kekahi mau manaʻo e pili ana i ka hiki ke hana i nā genena ma ka palekana a me ka hilinaʻi.

Top 10 Biologics

ʻO nā hua'ōlelo heʻumi i heluʻia ma lalo nei uaʻoi aku ka nui ma mua o ka ho'ākāka kālā o kahi "blockbuster" i kapa inoa i ka lāʻau i hanaʻia ma mua o $ 1 biliona i nā kūʻai makahiki.

I ka makahiki 2015, hoʻomaka nā kumu honua i ka hoʻokūkū mai nā biosimilars , aiʻole nā ​​biogenerics, i ka manawa i hakuʻia aiʻo Rituximab e IDEC Pharmaceuticals ma lalo o ka inoa IDEC-C2B8 . [1] Ua hoʻopukaʻia ka palapala noi US i ka makahiki 1998 a hoʻopauʻia i ka makahiki 2015. Ua halaʻo Humira i ka pale patent i ka makahiki 2016 a e lilo anaʻo Remicade i kāna mau pale i 2018.

ʻO nā kiʻi ma lalo nei no nā lā hope loa i hāʻawiʻia no kēlā me kēia huahana.

  • 01 Humira

    ʻO ka Humira-anti-inflammatory drug i hoʻoiliʻoleʻia ka lāʻau maikaʻi loa; ʻO ia ka lāʻau kūʻai maikaʻi loa ma ka honua nei, me kaʻole o ka papa.

    Hōʻike:ʻO ke kīpona Rheumatoid, plaque psoriasis, maʻi o Crohn, ulitisrative colitis, sparkylitis ankylosing; nā'ākia psoriatic, polyeticular juvenile idiopathic arthritis

    Ka mea i hana ai: AbbVie, a me nā Abbott Laboratories

    Global Sales ma 2015: $ 14 biliona

    Inoa inoa: Adalimumab

    Kākoʻo lā: 2002

  • 02 Hōʻike

    Hoʻomumu muaʻiaʻo Remicade e Centocor Ortho Biotech,ʻo iaʻo Janssen Biotech, kahi lālā Johnson & Johnson.

    Nń Kuhikuhi: O ka hawewe ole Rheumatoid, ka maʻi o Crohn, ka spondylitis ankylosing, ka psoriatic arthritis, plaque psoriasis, ulitisrative colitis

    Mea hana: Johnson & Johnson / Merck & Co.

    Global Sales ma 2015: $ 5.78 piliona

    ʻO ka inoa inoa pūnaewele: Infliximab

    Ke hoʻomaka lā: 1998

  • 03 Rituxan

    Hoʻokumuʻiaʻo Rituxan (rituximab) e IDEC Pharmaceuticals ma lalo o ka inoa IDEC-C2B8. Hāʻawiʻiaʻo Rituxan i kēia manawa ma keʻano kūʻai pāʻaniʻia maʻAmelika Hui Pūʻia e Biogen Idec a me Roche lālā Genentech.

    Hōʻike: Na lymphoma non-Hodgkins, maʻi leukemia lymphocytic mau loa,ʻo ka maʻi'ōmaʻomaʻo

    Mea hana: Roche

    Global Sales ma 2015: $ 7.32 piliona

    Kapa inoa inoa: Ritimimab

    Ke kūkāʻana i ka lā: 1997

  • 04 Enbrel

    Ua hoʻomohalaʻia ka'ōnaehana e nā poʻe noiʻi o Immunex. I kēia lā ua kūʻai likeʻia ka lāʻau lapaʻau ma Amelika a me Pfizer, e Takeda Pharmaceuticals ma Iapana a me Wyeth ma ke koena o ka honua.

    Hōʻike: Rathicatoid arthritis, plaque psoriasis, psoriatic arthritis

    Mea hana: Pfizer / Amgen

    Global Sales i 2016: $ 23 biliona

    Inoa inoa: Etanercept

    Ke hoʻomaka lā: 1998

  • 05 Lantus

    Ua hoʻolālāʻiaʻo Lantus ma kahi o kaʻimi no kaʻenehana koolaolaola Sanofi-Aventis ma Frankfurt-Höchst, Kelemānia.

    Hōʻike: Diabetes

    Mea Hana: Sanofi

    Global Sales ma 2015: $ 6.98 bila

    Ke inoa inoa: Insulin glangine [rDNA kumu] injection

    Ke Likana Hōʻike: 2000

  • 06 Avastin

    I ka hoʻomohalaʻiaʻana i ka makahiki 2004,ʻo Genentech's Avastin kekahi o nā lāʻau lapaʻauʻoi loa ma ke kāleka, me kahi hōʻai'ē kūʻai kālā he $ 4,400.

    Hōʻike: Nānā, pale,'ekepeke, kino liʻiliʻi liʻiliʻi, glioblastoma, maʻi maʻi'ōpiopio

    Mea hana: Roche

    Global Sales ma 2015: $ 6.95 piliona

    Inoa inoa: Bevacizumab

    Hoʻouka laha: 2004

  • 07 Iuliana

    Ua hoʻomohalaʻia Herceptin e Genentech, kahi lālā Roche, aʻo ke Kulanuiʻo Cancer Centerʻo Californa-Los Angeles 'Jonsson.

    Hōʻike: HER2 + maʻi kanulau

    Mea hana: Roche

    Global Sales ma 2015: $ 6.59 piliona

    Kapa inoa inoa: Trastuzumab

    Ke hoʻomaka lā: 1998

  • 08 Neulasta

    Hōʻike: Neutropenia e pili ana i ka neʻemaka maʻi āpau

    Mea hana: Amgen

    Global Sales i 2016: $ 4.6 piliona

    Kapa inoa inoa: Pegfilgrastim

    Kākoʻo lā: 2002

  • 09 Lucentis

    Hoʻokumuʻia e Genentech, ranibizumab, he injectable, mea kūʻaiʻia ma United States e Genentech a me Novartis ma waho o ka US.

    Hōʻike: Ke kuhiʻana o macular i pili i ka makahiki

    Mea hana: Roche, Novartis

    Global Sales ma 2015: $ 4.2 biliona

    Inoa inoa: Ranibizumab

    Hoʻouka lā: 2006

  • 10 Ke kauwela

    Kūlepaʻo Avonex i ka United States e Biogen Idec a ma Merck ma lalo o ka inoa inoaʻo Rebif.

    Ke Kōmikeʻo Gemanyʻo Fraunhofer Institute no ka Inihana Hana Hana a me ka Biotechnohana IGB a me CinnaGen Kamupene Cloned Interferon beta-1a a mai ka makahiki 2006 ua kūʻaiʻia ka lāʻau lāʻau e like me CinnoVex, heʻano likeʻole ma Iran.

    Hōʻike: Hua'ōlelo nui (MS)

    Mea hana: Biogen Idec

    Global Sales ma 2014: $ 3 biliona

    ʻO ka inoa inoa: Interferon beta-1a

    Kākoʻo lā: 1996

  • ʻO ka hoʻolaha maikaʻi i nā meaolaola i loko o ka paepae pūnaewele:

    He nui nāʻoihana lāʻau e pili ana i ka honua, me nā lāʻau lapaʻau no ka mālamaʻana i ka melanoma a me nā maʻi maʻi'ē aʻe. Ua māheleʻo Sanofi a me Regeneronhave i ka hoʻomohalaʻana i Alirocumab, kahi'ā'ī o ka monoclonal no ka hanaʻana i ka hypercholestemlemia. Ua loaʻaʻo Janssen i ka "breakthrough" o ka FDA no ka hoʻomōhalaʻana i kāna myeloma maʻamau,ʻo iaʻo Daratumumab, kahi antibody. Ua loaʻa hoʻiʻo Merck i ka hōʻailona hōʻailona hōʻailona e FDA no MK-3475, kahi'āpana monoclonal, i manaʻoʻia no ka hānai melanoma a me nā maʻi maʻi'ē aʻe.